An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
In our previous work we showed that dietary restriction initiated at puberty reduced prostate cancer development in the TRAMP mouse model. The current study was conducted to ascertain whether a dietary restriction regime would similarly reduce lesion development if imposed once tumor development was well established. Male TRAMP mice were maintained on an ad libitum diet until 20 weeks of age when proliferative prostate lesions are clearly evident. Mice were then subjected to a 20% restriction in dietary calories compared to matched controls, which were continued on ad libitum feeding. Mice were sacrificed at 20, 24, 32, and 39 weeks of age and proliferative epithelial lesions of the prostate were assessed using an established grading scheme. In this study, although dietary restriction reduced mean sex pluck weight (prostate and seminal vesicles), and mean grade of epithelial proliferative lesions in the dorsal and lateral lobes of the prostate, the effect was not as pronounced as was the case with dietary restriction from puberty. There was no relationship between serum insulin like growth factor (IGF-1) and prostate lesion grade. Additionally, we also report the relationship between lobe specific lesion development and SV40 immunostaining and, the occurance of neuroendocrine tumors (NETs) in the ventral prostate and urethra of the TRAMP mouse. NETs stained with high specificity and sensitivity for the neuroendocrine markers, synaptophysin and neuron-specific enolase (NSE), less for serotonin, but not for chromogranin A. NETs did not stain for cyclo-oxygenase-2 (COX-2) nor androgen receptor (AR). SV40 positive tubulo-acinar tumors seen occasionally in the kidney, did not stain for synaptophysin nor NSE.
Suttie
Andrew W
AW
Integrated Laboratory Systems, Research Triangle Park, North Carolina 27709, USA. asuttie@ils-inc.com
Dinse
Gregg E
GE
Nyska
Abraham
A
Moser
Glenda J
GJ
Goldsworthy
Thomas L
TL
Maronpot
Robert R
RR
D000230:Adenocarcinoma / Q000473:pathology* / Q000503:physiopathology; D000818:Animals; D015415:Biomarkers; D031204:Caloric Restriction; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D018358:Neuroendocrine Tumors / Q000201:enzymology / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D009929:Organ Size / Q000502:physiology; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D016708:Synaptophysin / Q000378:metabolism; D013997:Time Factors
D015415:Biomarkers; D016708:Synaptophysin; D010751:Phosphopyruvate Hydratase